Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 9:9:572.
doi: 10.3389/fonc.2019.00572. eCollection 2019.

Prediction of Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging

Affiliations
Free PMC article

Prediction of Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging

Cheng Wei et al. Front Oncol. .
Free PMC article

Abstract

Objectives: To determine the prognostic significance of tissue stiffness measurement using transrectal ultrasound shear wave elastography in predicting biochemical recurrence following radical prostatectomy for clinically localized prostate cancer. Patients and Methods: Eligible male patients with clinically localized prostate cancer and extraperitoneal laparoscopic radical prostatectomy between November 2013 and August 2017 were retrospectively selected. Information of potential biochemical recurrence predictors, including imaging (ultrasound shear wave elastography and magnetic resonance imaging), clinicopathological characteristics, and preoperative prostate specific antigen (PSA) levels were obtained. Recurrence-free survival (Kaplan-Meier curve) and a multivariate model were constructed using Cox regression analysis to evaluate the impact of shear wave elastography as a prognostic marker for biochemical recurrence. Results: Patients experienced biochemical recurrence in an average of 26.3 ± 16.3 months during their follow-up. A cutoff of 144.85 kPa for tissue stiffness measurement was estimated for recurrence status at follow-up with a sensitivity of 74.4% and a specificity of 61.7%, respectively (p < 0.05). In univariate analysis, shear wave elastography performed well in all preoperative factors compared to biopsy Gleason Score, PSA and magnetic resonance imaging; in multivariate analysis with postoperative pathological factors, shear wave elastography was statistically significant in predicting postoperative biochemical recurrence, which improved the C-index of predictive nomogram significantly (0.74 vs. 0.70, p < 0.05). Conclusions: The study revealed that quantitative ultrasound shear wave elastography-measured tissue stiffness was a significant imaging marker that enhanced the predictive ability with other clinical and histopathological factors in prognosticating postoperative biochemical recurrence following radical prostatectomy for clinically localized prostate cancer.

Keywords: biochemical recurrence; nomogram; prostate cancer; radical prostatectomy; ultrasound shear wave elastography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Examples of BCR and BCR-free patients in comparison of SWE and clinicopathology data.
Figure 2
Figure 2
Flowchart of study.
Figure 3
Figure 3
ROC curve of USWE (left) and PSAD (right) for differentiating BCR and BCR free of PCa after radical surgery.
Figure 4
Figure 4
Kaplan–Meier curves of BCR-free survival in four significant predictors: (A) ultrasound shear wave elastography (USWE); (B) surgical margin (SM); (C) seminal vascular invasion (SVI); (D) pathology Gleason Score (pGS).
Figure 5
Figure 5
The nomograms of postoperative BCR prediction with (A1) and without USWE (A2). Calibration plots of actual and nomogram-predicted probability of BCR with (B1) and without USWE (B2).

Similar articles

Cited by

References

    1. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. . Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. (2005) 366:572–8. 10.1016/s0140-6736(05)67101-2 - DOI - PubMed
    1. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. (2005) 23:6139–48. 10.1200/jco.2005.08.156 - DOI - PubMed
    1. Suardi N, Capitanio U, Chun FKH, Graefen M, Perrotte P, Schlomm T, et al. . Currently used criteria for active surveillance in men with low-risk prostate cancer. Cancer. (2008) 113:2068–72. 10.1002/cncr.23827 - DOI - PubMed
    1. Mitterberger M, Horninger W, Aigner F, Pinggera GM, Steppan I, Rehder P, et al. . Ultrasound of the prostate. Cancer Imaging. (2010) 10:40–8. 10.1102/1470-7330.2010.0004 - DOI - PMC - PubMed
    1. Oehr P, Bouchelouche K. Imaging of prostate cancer. Curr Opin Oncol. (2007) 19:259–64. 10.1097/CCO.0b013e3280ad439b - DOI - PubMed